Summary:

• Small proof of concept study

• Patient cohort had long covid

• Ampligen well tolerated

• Ampligen reduced fatigue more than placebo at some points in the 13 week study

• Full press release in [the link(https://aimimmuno.com/aim-immunotech-reports-positive-topline-results-from-phase-2-study-evaluating-ampligen-for-the-treatment-of-post-covid-conditions/).